Related Experiment Video
Updated: Jul 5, 2025
Development of a Backbone Cyclic Peptide Library as Potential Antiparasitic Therapeutics Using Microwave Irradiation
Published on: January 26, 2016
DP1, a multifaceted synthetic peptide: Mechanism of action, activity and clinical potential
Mayank Maan1, Hemant Goyal1, Shubhi Joshi1
1Department of Biophysics, Panjab University, Chandigarh, U.T. 160014, India.
Aims:
Microbial infections remain a leading cause of mortality worldwide, with Staphylococcus aureus (S. aureus) being a prominent etiological agent, responsible for causing persistent bacterial infections in humans. It is a nosocomial, opportunistic pathogen, capable to propagate within the bloodstream and withstand therapeutic interventions. In the current study, a novel, indigenously designed synthetic antimicrobial peptide (sAMP) has been evaluated for its antimicrobial potential to inhibit the growth and proliferation of S. aureus.
Main Methods:
The sAMP, designed peptide (DP1) was evaluated for its minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) against a panel of pathogenic bacterial strains. Membrane mechanistic studies were performed by measuring membrane conductivity via dielectric spectroscopy and visualizing changes in bacterial membrane structure through field emission scanning electron microscopy (FE-SEM). Further, DP1 was tested for its in vivo antimicrobial potential in an S. aureus-induced systemic infection model.
Key Findings:
The results indicated that DP1 has the potential to inhibit the growth and proliferation of a broad spectrum of Gram-positive, Gram-negative and multidrug-resistant (MDR) bacterial strains. Strong bactericidal effect attributed to change in electrical conductivity of the bacterial cells leading to membrane disruption was observed through dielectric spectroscopy and FE-SEM micrographs. Further, in the in vivo murine systemic infection study, 50 % reduction in S. aureus bioburden was observed within 1 day of the administration of DP1.
Significance:
The results indicate that DP1 is a multifaceted peptide with potent bactericidal, antioxidant and therapeutic properties. It holds significance as a novel drug candidate to effectively combat S. aureus-mediated systemic infections.
Insights
A novel synthetic antimicrobial peptide (sAMP), DP1, effectively inhibits Staphylococcus aureus growth and reduces bacterial burden in vivo. DP1 shows potent bactericidal properties, offering a promising therapeutic candidate for S. aureus infections.
Area of Science:
- Microbiology
- Infectious Diseases
- Drug Discovery
Background:
- Microbial infections, particularly Staphylococcus aureus (S. aureus), are a major global health concern.
- S. aureus is a significant nosocomial pathogen causing persistent and difficult-to-treat infections.
- There is a critical need for novel therapeutic strategies against antibiotic-resistant bacteria.
Purpose of the Study:
- To evaluate the antimicrobial potential of a novel synthetic antimicrobial peptide (sAMP), designated DP1.
- To assess DP1's efficacy against Staphylococcus aureus, including multidrug-resistant strains.
- To investigate the mechanism of action and in vivo therapeutic potential of DP1.
Main Methods:
- DP1's minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) were determined.
- Membrane disruption was studied using dielectric spectroscopy and field emission scanning electron microscopy (FE-SEM).
- In vivo efficacy was assessed in a mouse model of S. aureus systemic infection.
Main Results:
- DP1 demonstrated broad-spectrum activity against Gram-positive, Gram-negative, and multidrug-resistant bacteria.
- Dielectric spectroscopy and FE-SEM confirmed DP1 disrupts bacterial cell membranes.
- In vivo studies showed a 50% reduction in S. aureus bioburden within 24 hours of DP1 administration.
Conclusions:
- DP1 exhibits potent bactericidal activity and disrupts bacterial membranes.
- DP1 possesses antioxidant and therapeutic properties, indicating multifaceted action.
- DP1 represents a promising novel drug candidate for treating S. aureus systemic infections.
More Related Videos
09:06Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression
Published on: February 3, 2023
10:18Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
Published on: July 7, 2023
Related Concept Videos
01:24Principles of Drug Action
Drugs can be agonists or antagonists. Like the endogenous ligands, agonists always bind and activate the target to produce a cellular response. Agonist binding induces a conformational change which in turn...
01:28Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
01:24Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
01:16Adrenergic Agonists: Chemistry and Structure-Activity Relationship
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
01:21Antipsychotic Drugs: Typical and Atypical Agents
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...